A group of scientists tested the effectiveness and tolerance of cannabidiol (CBD)-based drug Epidiolex against Parkinson’s at low doses.
Researchers realized that low doses are effective in reducing symptoms related to this disease. However, high doses were associated with elevations of liver enzymes.
The study was conducted by the Department of Neurology at the Colorado School.
“CBD, in the form of Epidiolex, may be effective in PD, but the relatively high dose used in this study was associated with elevations of liver enzymes. Randomized controlled trials are needed to investigate various forms of cannabis in PD. “
Read the full investigation: https://www.liebertpub.com/doi/10.1089/can.2019.0068
in Costa Rica. 
